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TO THE EDITOR
A major concern when surveying phy-
sicians via mailed questionnaires is the
potential raised by low response rates
for nonresponse bias (i.e., the possibi-
lity that those individuals who com-
plete a survey are different in some way
than those who do not complete a
survey; Tambor et al., 1993; Halpern
et al., 2002). While low response rates
do not automatically lead to this type of
bias, the possibility for nonresponse
bias is higher when the response rate
is low (Cummings et al., 2001; Halpern
and Asch, 2003).
Three interventions that may in-
crease response rates and that have
not yet been adequately investigated
are hand-written personalized notes on
the introductory cover letter accompa-
nying the survey instrument, hand-
written signatures and notes on a
reminder postcard, and inclusion of
hard candy in mailings as a material
incentive. We investigated the effect of
these three interventions in a mailed
survey of 800 dermatologists randomly
assigned to groups that would either
receive or not receive each of the three
interventions (Table 1). This study was
approved by the Institutional Review
Board of the University of Pennsylvania
School of Medicine. We mailed a four-
page survey on physician attitudes and
beliefs surrounding dysplastic nevi to
800 randomly selected members of the
American Academy of Dermatology
with mailing addresses in the United
States. (The results of the survey and
additional details regarding the survey
instrument can be found in Shapiro
et al., 2004.) Our mailing protocol, a
modification of the Dillman Tailored
Design Method (Dillman, 1999), in-
cluded an initial mailing of a cover
letter and survey, a reminder postcard
sent 1–2 weeks later, and a second
mailing of the survey to those who
had not yet responded approximately
6 weeks after the initial mailing. The
initial cover letter included the recipi-
ent’s name and address and a brief
summary of the study, and it concluded
with preprinted signatures of the inves-
tigators.
Subjects were randomly assigned to
one of the eight groups using a
222 factorial design (Table 1) so
that half of the subjects received a
personalized hand-written note on the
cover letter for the initial mailing and
half did not; half of the subjects
received three hard candies (large-size
LifeSavers ‘‘Wintogreen’’ mints, indivi-
dually wrapped, each B2.5 cm in
diameter) in the initial mailing and half
did not; and half of the subjects
received a reminder postcard with a
hand-written signature with ‘‘Thank
you!’’ hand-written next to it, while
the other half received a reminder
postcard containing a preprinted signa-
ture only. The personalized note in
the initial mailing was at the top of
the cover letter, personally addressed to
the recipient, with the following hand-
written text: ‘‘Dear Dr XX, We’d greatly
appreciate your participation. Sin-
cerely, Michael Ming,’’ with Dr Ming’s
hand-written signature. The second
mailing of the survey did not contain
the personalized note or the hard
candy.
Comparisons were made by w2-analy-
sis using Stata 6.0 (Stata, College Station,
TX). With 400 subjects in each interven-
tion and control group, the study had
81% power at the level of a¼0.05 to
detect a difference of at least 10% from a
baseline response rate of 50%.
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Of the 800 dermatologists who were
sent surveys, 28 (3.5%) were found
to be ineligible (they had either died
(15 subjects), been assigned an incor-
rect address (12 subjects), or were not a
dermatologist (1 subject)), leaving 772
subjects. The overall response rate was
56.0% (432/772), with responses from
42 states and the District of Columbia.
Fourteen (1.8%) subjects responded
that they did not wish to participate in
the overall survey by the protocol
outlined in the cover letter, which was
to return a blank survey in the provided
postage-paid reply envelope. There was
no significant difference between dif-
ferent groups in the proportion of
respondents declining to participate in
the overall survey.
Overall, 60.9% (237/389) of the
physicians receiving the personalized
note on the cover letter responded
compared to 50.9% (195/383) of those
who did not receive the personalized
note (P¼0.005; Table 2), an increase of
10%. In total, 59.6% (230/386) of the
physicians who received a hand-written
signature and note on the reminder
postcard responded compared with
52.3% (202/386) of those who received
a preprinted signature on the reminder
postcard (P¼ 0.04), an increase of
7.3%. In all, 56.8% (218/384) of the
physicians receiving candy responded
compared with 55.1% (214/388) of
those who did not receive candy
(P¼0.56), which was not a statistically
significant increase.
Our findings suggest that a persona-
lized signature or note, even on the
reminder postcards, has a significant
impact in one’s decision to respond to a
survey. The increases from personaliza-
tion found in this study are slightly
higher than the rate of 5–8% suggested
by previous authors using other meth-
ods of personalization, although there
are few randomized controlled trials on
the subject (Dillman, 1999).
The inclusion of hard candy did
not appear to increase the response
rate in our study population. A similar
study using mints with general practi-
tioners and internists also found no
impact (Halpern et al., 2002). Candy
appears to be an ineffective material
incentive for physicians, who have
been shown to increase response rates
with receiving $5 or $10, but generally
not with token nonmonetary incentives
(Asch et al., 1998; Field et al.,
2002). Candy has also been hypothe-
sized to improve response by increasing
package bulk and therefore raising
interest in its contents (Halpern et al.,
2002); our candy may have been
too small for this to be an important
factor.
To the best of our knowledge, this is
the first randomized controlled trial that
quantifies the increase in response rate
of the first two methods, and the first
study of any kind examining potential
methods for increasing response rates
for dermatologists. We have found that
personalized signatures and notes on
both introductory cover letters and
reminder postcards are effective and
straightforward ways to increase respo-
nse rates of mailed surveys for dermato-
logists by approximately 7–10%, while
hard candy incentive does not appear
to be effective. Such methods may be
cost-effective ways of increasing survey
response rate.
Table 1. Subject groups (100 subjects in each group)
100 Subjects 100 Subjects 100 Subjects 100 Subjects
K Hand-written note on the
initial cover letter
K Hand-written note on the
initial cover letter
K Hand-written note on the initial
cover letter
K Hand-written note on the initial
cover letter
K Candy K No candy K Candy K No candy
K Hand-written signature and
note on the reminder postcard
K Hand-written signature and
note on the reminder postcard
K No hand-written signature and
note on the reminder postcard
K No hand-written signature and
note on the reminder postcard
K No hand-written note on the
initial cover letter
K No hand-written note on the
initial cover letter
K No hand-written note on the
initial cover letter
K No hand-written note on the
initial cover letter
K Candy K No candy K Candy K No candy
K Hand-written signature and
note on the reminder postcard
K Hand-written signature and
note on the reminder postcard
K No hand-written signature and
note on the reminder postcard
K No hand-written signature and
note on the reminder postcard
Table 2. Response rates by intervention
Number of responses Response rate (%) P-value
Hand-written note on the cover letter
Present 237/389 60.9
Absent 195/383 50.9 0.005
Hand-written signature on postcard
Present 230/386 59.6
Absent 202/386 52.3 0.04
Hard candy
Present 218/384 56.8
Absent 214/388 55.1 0.56
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TO THE EDITOR
Anti-tumor necrosis factor-a (TNF-a)
drugs (mAbs infliximab (IFX) and
adalimumab (ADA), and soluble TNF-
a receptor etanercept (ETA)) are used
for rheumatoid arthritis (RA), spondy-
larthropathies, psoriasis, Crohn’s dis-
ease, and ulcerative colitis. These
molecules increase the risk of various
pathogens such as Mycobacterium tu-
berculosis (Flynn et al., 1995; Tubach
et al., 2009) or trigger reactivation of
varicella zoster virus (VZV) and
subsequently herpes zoster (HZ). The
Spanish registry showed more frequent
hospitalizations because of VZV
infection for patients receiving anti-
TNF-a therapy than expected in the
general population (Garcı´a-Doval
et al., 2010), and the German registry
demonstrated an increased risk of
HZ and severe HZ as well (Strangfeld
et al., 2009). We aimed to identify
the risk factors and describe the out-
come of HZ for patients receiving TNF-
a blockers for severe inflammatory
conditions.
The French RATIO registry was
designed to prospectively collect all
cases of opportunistic infections in
metropolitan France from 1 February
2004 to 31 January 2007 in patients
who were receiving or had received
anti-TNF-a treatment. This registry in-
cludes cases from clinicians, pharma-
covigilance centers of the French
agency of drugs (Agence Franc¸aise de
Se´curite´ Sanitaire des Produits de
Sante´), and companies commercializ-
ing anti-TNF-a therapy. The methodo-
logical details have been described
elsewhere (Tubach et al., 2005, 2009).
A committee of three experts in oppor-
tunistic infections (OC, DS-C, and OL)
reviewed detailed standardized case
report forms and additional documents
for all reported HZ cases. We con-
ducted a case–control study to investi-
gate the risk factors of HZ for patients
receiving anti-TNF-a therapy. Cases
were validated HZ cases being treated
for a labeled indication, and controls
were patients from centers involved in
the RATIO registry who were being
treated with anti-TNF-a therapy (current
treatment or stopped for o24 months)
for a labeled indication and never
exhibited HZ during the follow-up
period. The control pool has been
described elsewhere (Salmon-Ceron
et al., 2011). Four controls per case
were matched by underlying inflamma-
tory disease.
We validated 24 HZ cases (18
women, mean age 54.4 years, 79%
receiving anti-TNF-a therapy for RA,
median time from onset of last anti-TNF
agent to HZ occurrence 11.5 years
(interquartile range 4.2–24.3)). Clinical
characteristics and outcomes are shown
in Table 1. The last anti-TNF agent
received was ADA, IFX, and ETA in
10 (14.7%), 9 (37.5%), and 5 (20.8%)
cases, respectively. Eight cases, invol-
ving at least two distinct episodes, more
than one dermatome, the central ner-
vous system, or the eye, were consid-
ered severe HZ, as recently defined
by the RATIO group (Salmon-Ceron
et al., 2011): one clinically sympto-
matic meningitis with positive local
results on PCR, four multidermatomal
locations, one secondary generalized
and recurrent HZ, and three ophthalmic
Abbreviations: ADA, adalimumab; ETA, etanercept; HZ, herpes zoster; IFX, infliximab; RA, rheumatoid
arthritis; TNF-a, tumor necrosis factor-a; VZV, varicella zoster virus
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